You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The molecular diagnostics firm anticipates fetching between $12 and $14 per share in its IPO for net proceeds of $52.2 million at the midpoint price of $13 per share.
BGI's spinoff companies, BGI Tech and BGI Dx, have merged and will go public next year.
Invitae offers NGS-based panels for a range of genetic conditions in the fields of cardiology, hereditary cancer, pediatric genetics, neurology, and hematology.
HTG plans to list its shares on the Nasdaq and is the 11th firm this year in the MDx/omics tools space to either go public or file for an IPO.
Pressures, including reimbursements and flat NIH funding, continued to dampen M&A in the past year, but one expert said that the picture may be brighter than it appears.
In an SEC document, the company called current market conditions for an IPO unattractive.
The firm offers a portfolio of genetic tests to help clinicians tailor treatments for patients suffering from cardiovascular disease, neuropsychiatric disorders, and pain.
The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.
Melanoma test development firm DermTech is pulling its proposed initial public offering.
NEW YORK (GenomeWeb) — Molecular diagnostics firm Great Basin Scientific has priced a planned initial public offering of 1.15 million units, with each unit consisting of one share of common stock and one Series A warrant.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.